EUVIMEDEUVIMED entdecken
Beobachtungsstudie

5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center

Xiang Li, Yiwen Chen, Guoliang Qiao, Jian Ni, Tao Chen, Yangyang Wang, Chengyi Wu, Qi Zhang, Tao Ma, Shunliang Gao, Min Zhang, Yan Shen und 9 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217658 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Letters, 2025. Verfasst von Xiang Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Innovat…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standardized clinical management of pancreatic adenocarcinoma (PDAC) remains challenging and high-volume centers provide essential insights for establishing effective multimodal treatment approaches. This retrospective observational study evaluated the impact of standardized, multimodal clinical management on survival outcomes in patients with PDAC across all stages, based on NCCN guidelines resectability criteria, at a high-volume center. From 2019, 4143 patients were diagnosed with PDAC, with 3268 patients receiving further treatment, including surgical resection and/or systemic therapy. The median overall survival (OS) was 18.5 (95 %CI 17.5-19.4) months for the treated cohort and the 5-year survival rate reached 23.3 %. Patients who underwent surgical resection had significantly improved median OS compared to those who received non-surgical treatments (28.4 months vs. 13.0 months, P < 0.001), with corresponding 5-year survival rates of 31.6 % vs. 15.0 %. Moreover, the patients who received NAT followed by surgical resection had improved survival outcomes compared to those who underwent upfront surgical resection in both resectable (median OS: 37.5 months vs. 28.9 months, P < 0.01) and borderline resectable group (median OS: 31.8 months vs. 18.4 months, P < 0.001). This study demonstrated a 5-year survival rate exceeding 20 % for PDAC across all stages at our center. The application of evidence-based treatment strategies through the multidisciplinary team, accompanying with standardized and comprehensive therapeutic managements, high patient adherence, have been considered as critical determinants in enhancing therapeutic efficacy and improving long-term prognosis for patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedChinaCombined Modality TherapyHospitals, High-VolumePancreatectomyRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

High-volume centerMultimodal treatmentPancreatic ductal adenocarcinomaResectabilitySurvival rate

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province,…
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Information Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Radiology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Ultrasound, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Zitieren

APA

Li, X., Chen, Y., Qiao, G., Ni, J., Chen, T., Wang, Y., Wu, C., Zhang, Q., Ma, T., Gao, S., Zhang, M., Shen, Y., Wu, J., Yu, J., Que, R., Zhang, X., Sun, K., Xiao, W., Jiang, T., …, & Liang, T. (2025). 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217658

Vancouver

Li X, Chen Y, Qiao G, Ni J, Chen T, Wang Y, et al. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217658

BibTeX
@article{Li2025,
  author = {Li, Xiang and Chen, Yiwen and Qiao, Guoliang and Ni, Jian and Chen, Tao and Wang, Yangyang and Wu, Chengyi and Zhang, Qi and Ma, Tao and Gao, Shunliang and Zhang, Min and Shen, Yan and Wu, Jian and Yu, Jun and Que, Risheng and Zhang, Xiaochen and Sun, Ke and Xiao, Wenbo and Jiang, Tian'an and Bai, Xueli and Liang, Tingbo},
  title = {5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217658}
}
Kostenlos starten →